Skip to main content

A feasibility study on the development of Psorax35 as the first and only oral treatment for mild-to-moderate psoriasis with positive effects on co-morbidities.

Project description

Development of the first oral treatment for mild-to-moderate psoriasis

Call for proposal

H2020-SMEInst-2018-2020-1
See other projects for this call

Funding Scheme

SME-1 - SME instrument phase 1

Coordinator

ARCTIC NUTRITION AS
Address
Industrivegen 42
6155 Orsta
Norway
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
EU contribution
€ 50 000